{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:28:08Z","timestamp":1791041288492,"version":"4.1.0"},"reference-count":45,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1210\/jc.2018-00470","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T14:21:23Z","timestamp":1527603683000},"page":"3019-3027","source":"Crossref","is-referenced-by-count":96,"title":["Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol"],"prefix":"10.1210","volume":"103","author":[{"given":"Gregory A","family":"Nichols","sequence":"first","affiliation":[{"name":"Kaiser Permanente Center for Health Research, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[{"name":"Amarin Pharma Inc., Bedminster, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B","family":"Granowitz","sequence":"additional","affiliation":[{"name":"Amarin Pharma Inc., Bedminster, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"issue":"13","key":"key\n\t\t\t\t20180806135351_B1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCULATIONAHA.108.829176","article-title":"Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005","volume":"119","author":"Preis","year":"2009","journal-title":"Circulation"},{"issue":"23","key":"key\n\t\t\t\t20180806135351_B2","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa0908610","article-title":"Population trends in the incidence and outcomes of acute myocardial infarction","volume":"362","author":"Yeh","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"key\n\t\t\t\t20180806135351_B3","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1161\/CIRCULATIONAHA.111.047480","article-title":"Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008","volume":"125","author":"Rosamond","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"key\n\t\t\t\t20180806135351_B4","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2337\/dc11-1162","article-title":"Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey","volume":"35","author":"Gregg","year":"2012","journal-title":"Diabetes Care"},{"issue":"3","key":"key\n\t\t\t\t20180806135351_B5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/CIRCULATIONAHA.108.846519","article-title":"Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study","volume":"120","author":"Preis","year":"2009","journal-title":"Circulation"},{"issue":"10","key":"key\n\t\t\t\t20180806135351_B6","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics\u20142017 Update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"22","key":"key\n\t\t\t\t20180806135351_B7","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1001\/jama.2016.13645","article-title":"US county-level trends in mortality rates for major causes of death, 1980\u20132014","volume":"316","author":"Dwyer-Lindgren","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180806135351_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"23","key":"key\n\t\t\t\t20180806135351_B9","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"key\n\t\t\t\t20180806135351_B10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"key\n\t\t\t\t20180806135351_B11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the treating to new targets and incremental cecrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am J Cardiol"},{"issue":"21","key":"key\n\t\t\t\t20180806135351_B12","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"key\n\t\t\t\t20180806135351_B13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"issue":"1","key":"key\n\t\t\t\t20180806135351_B14","first-page":"1049","article-title":"The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration","volume":"2","author":"Ross","year":"2014","journal-title":"EGEMS (Wash DC)"},{"issue":"3","key":"key\n\t\t\t\t20180806135351_B15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"issue":"2","key":"key\n\t\t\t\t20180806135351_B16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"issue":"18","key":"key\n\t\t\t\t20180806135351_B17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"key\n\t\t\t\t20180806135351_B18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-014-0159-y","article-title":"Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor","volume":"13","author":"Tenenbaum","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"key\n\t\t\t\t20180806135351_B19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"issue":"17","key":"key\n\t\t\t\t20180806135351_B20","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/01.CIR.0000145615.33955.83","article-title":"Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region","volume":"110","author":"Patel","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180806135351_B21","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2337\/dc18-S010","article-title":"10. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2018.","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180806135351_B22","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"9. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2018.","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"issue":"20","key":"key\n\t\t\t\t20180806135351_B23","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"key\n\t\t\t\t20180806135351_B24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4239\/wjd.v5.i5.577","article-title":"Peripheral arterial disease, type 2 diabetes and postprandial lipidaemia: is there a link","volume":"5","author":"Valdivielso","year":"2014","journal-title":"World J Diabetes"},{"issue":"24","key":"key\n\t\t\t\t20180806135351_B25","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"key\n\t\t\t\t20180806135351_B26","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"issue":"9713","key":"key\n\t\t\t\t20180806135351_B27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(09)61969-3","article-title":"Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study","volume":"375","author":"Currie","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"key\n\t\t\t\t20180806135351_B28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jacc.2013.04.031","article-title":"Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality","volume":"62","author":"Nichols","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key\n\t\t\t\t20180806135351_B29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9149(92)90550-I","article-title":"Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular M\u00fcnster study","volume":"70","author":"Assmann","year":"1992","journal-title":"Am J Cardiol"},{"issue":"9","key":"key\n\t\t\t\t20180806135351_B30","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"key\n\t\t\t\t20180806135351_B31","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"issue":"6","key":"key\n\t\t\t\t20180806135351_B32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archinternmed.2008.599","article-title":"Hypertriglyceridemia and its pharmacologic treatment among US adults","volume":"169","author":"Ford","year":"2009","journal-title":"Arch Intern Med"},{"issue":"1","key":"key\n\t\t\t\t20180806135351_B33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2016.04.004","article-title":"Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease","volume":"118","author":"Budoff","year":"2016","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180806135351_B34","unstructured":"ClinicalTrials.gov. Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH). Accessed 2017. clinicaltrials.gov\/ct2\/show\/NCT02104817."},{"key":"key\n\t\t\t\t20180806135351_B35","unstructured":"ClinicalTrials.gov. Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT). Accessed 2017. clinicaltrials.gov\/ct2\/show\/NCT03071692."},{"issue":"3","key":"key\n\t\t\t\t20180806135351_B36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"key\n\t\t\t\t20180806135351_B37","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"key\n\t\t\t\t20180806135351_B38","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglycerides and Impact on Global Health Outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"key\n\t\t\t\t20180806135351_B39","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jacc.2015.12.047","article-title":"Fasting or nonfasting lipid measurements: it depends on the question","volume":"67","author":"Driver","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key\n\t\t\t\t20180806135351_B40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"key\n\t\t\t\t20180806135351_B41","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"key\n\t\t\t\t20180806135351_B42","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.163.9.1077","article-title":"Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease","volume":"163","author":"Eberly","year":"2003","journal-title":"Arch Intern Med"},{"issue":"10","key":"key\n\t\t\t\t20180806135351_B43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0002-9149(01)02047-1","article-title":"Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease","volume":"88","author":"Schaefer","year":"2001","journal-title":"Am J Cardiol"},{"issue":"8","key":"key\n\t\t\t\t20180806135351_B44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2017.9991","article-title":"Multidimensional evidence generation and FDA regulatory decision making: defining and using \u201creal-world\u201d data","volume":"318","author":"Jarow","year":"2017","journal-title":"JAMA"},{"issue":"23","key":"key\n\t\t\t\t20180806135351_B45","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/8\/3019\/25407555\/jc.2018-00470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T15:52:54Z","timestamp":1571413974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/103\/8\/3019\/5005949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,5,29]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-00470","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,5,29]]}}}